91�� News - RNA therapeutics

D2R awards over $5.3 million in Foundational and Research in Motion funding programs

webfull — Thu, 06 Nov 2025 18:13:29 +0000

Montreal – November 6, 2025 | The DNA to RNA (D2R) initiative at 91�� is proud to announce the recipients of the second cycle of the Foundational and Research in Motion (RIM) funding programs.

From common diseases affecting millions, such as lung cancer, to rare disorders like lipodystrophy, this investment of over 5.3 million dollars reflects D2R’s commitment to advancing bold ideas and fostering interdisciplinary collaboration across the discovery-to-implementation spectrum.

Published: 6 November 2025

Event | Breast Cancer & RNA Therapeutics: Exploring inclusive research and career opportunities

webfull — Fri, 03 Oct 2025 20:53:13 +0000

Join D2R and the Rosalind and Morris Goodman Cancer Institute (GCI) for an event in honour of Breast Cancer Awareness Month and Women's History Month, in collaboration with Fondation du cancer du sein du Québec and the association Audace au féminin.

Published: 3 October 2025

Event | AReNA "From Mission to Action"

webfull — Thu, 18 Sep 2025 17:40:36 +0000

AReNA, Québec’s RNA Hub, is inviting everyone involved in the field of RNA in Québec—researchers, innovators, institutions, partners, anyone curious about the field, as well as experts—to attend the event "From Mission to Action" on October 16, 2025 at the BAnQ in Montréal.

This event is intended to celebrate a year of collective impact with presentations, discussions and networking, as well as to reconnect and collectively reflect on RNA therapies in Québec.

Published: 18 September 2025

Event | Seminar: Computer-based Predictions of RNA Structures: Where do we stand?

webfull — Thu, 04 Sep 2025 13:11:03 +0000

Join D2R for this hybrid seminar with Professor Eric Westhof from University of Strasbourg

Published: 4 September 2025

91�� awards $500,000 to accelerate Mpox research and vaccine development

webfull — Thu, 13 Feb 2025 12:07:55 +0000

Montreal, February 13, 2025 – 91��’s DNA to RNA Initiative (D2R) and 91�� Interdisciplinary Initiative in Infection and Immunity (MI4) have awarded $500,000 to fund five high-impact research projects aimed at advancing the understanding of Mpox through its Rapid Response for Mpox Research funding program.

Published: 13 February 2025

D2R awards over $6 million to support Core Platforms

webfull — Fri, 07 Feb 2025 14:37:46 +0000

The D2R (DNA to RNA) Initiative has awarded more than $6 million to support eight Core Platforms at 91�� and one at the University of British Columbia through its Core Platform Sustainability funding program. This program supports state-of-the-art Core Platforms that are essential for advancing research and development and facilitating technology uptake and transfer in fields relevant to RNA therapeutics.

Published: 7 February 2025

91������ News - RNA therapeutics